{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:07:15Z","timestamp":1789132035422,"version":"build-2803163510"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"\n Importance<\/jats:title>\n Federal emergency authorities were invoked during the COVID-19 pandemic to expand use of telehealth for new and continued care, including provision of medications for opioid use disorder (MOUD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine receipt of telehealth services, MOUD (methadone, buprenorphine, and extended-release [ER] naltrexone) receipt and retention, and medically treated overdose before and during the COVID-19 pandemic.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This exploratory longitudinal cohort study used data from the US Centers for Medicare &amp;amp; Medicaid Services from September 2018 to February 2021. Two cohorts (before COVID-19 pandemic from September 2018 to February 2020 and during COVID-19 pandemic from September 2019 to February 2021) of Medicare fee-for-service beneficiaries 18 years and older with an\n International Statistical Classification of Diseases, Tenth Revision, Clinical Modification<\/jats:italic>\n OUD diagnosis.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Pre\u2013COVID-19 pandemic vs COVID-19 pandemic cohort demographic characteristics, medical and substance use, and psychiatric comorbidities.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Receipt and retention of MOUD, receipt of OUD and behavioral health-related telehealth services, and experiencing medically treated overdose.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The pre\u2013COVID-19 pandemic cohort comprised 105\u202f240 beneficiaries; of these, 61\u202f152 (58.1%) were female, 71\u202f152 (67.6%) were aged 45 to 74 years, and 82\u202f822 (79.5%) non-Hispanic White. The COVID-19 pandemic cohort comprised 70\u202f538 beneficiaries; of these, 40\u202f257 (57.1%) were female, 46\u202f793 (66.3%) were aged 45 to 74 years, and 55\u202f510 (79.7%) were non-Hispanic White. During the study period, a larger percentage of beneficiaries in the pandemic cohort compared with the prepandemic cohort received OUD-related telehealth services (13\u202f829 [19.6%] vs 593 [0.6%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), behavioral health-related telehealth services (28\u202f902 [41.0%] vs 1967 [1.9%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and MOUD (8854 [12.6%] vs 11\u202f360 [10.8%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The percentage experiencing a medically treated overdose during the study period was similar (18.5% [19\u202f491 of 105\u202f240] in the prepandemic cohort vs 18.4% [13\u202f004 of 70\u202f538] in the pandemic cohort;\n P<\/jats:italic>\n \u2009=\u2009.65). Receipt of OUD-related telehealth services in the pandemic cohort was associated with increased odds of MOUD retention (adjusted odds ratio [aOR], 1.27; 95% CI, 1.14-1.41) and lower odds of medically treated overdose (aOR, 0.67; 95% CI, 0.63-0.71). Among beneficiaries in the pandemic cohort, those receiving MOUD from opioid treatment programs only (aOR, 0.54; 95% CI, 0.47-0.63) and those receiving buprenorphine from pharmacies only (aOR, 0.91; 95% CI, 0.84-0.98) had lower odds of medically treated overdose compared with beneficiaries who did not receive MOUD.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Emergency authorities to expand use of telehealth and provide flexibilities for MOUD provision during the pandemic were used by Medicare beneficiaries initiating an episode of OUD-related care and were associated with improved retention in care and reduced odds of medically treated overdose. Strategies to expand provision of MOUD and increase retention in care are urgently needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.2284","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T11:32:25Z","timestamp":1661945545000},"page":"981","source":"Crossref","is-referenced-by-count":139,"title":["Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic"],"prefix":"10.1001","volume":"79","author":[{"given":"Christopher M.","family":"Jones","sequence":"first","affiliation":[{"name":"National Center for Injury Prevention and Control, US Centers for Disease Control & Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Shoff","sequence":"additional","affiliation":[{"name":"Information Products and Analytics Group, US Centers for Medicare & Medicaid Services, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hodges","sequence":"additional","affiliation":[{"name":"Information Products and Analytics Group, US Centers for Medicare & Medicaid Services, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Blanco","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan L.","family":"Losby","sequence":"additional","affiliation":[{"name":"National Center for Injury Prevention and Control, US Centers for Disease Control & Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari M.","family":"Ling","sequence":"additional","affiliation":[{"name":"US Centers for Medicare & Medicaid Services, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson M.","family":"Compton","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi220048r4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics.","volume":"173","author":"Volkow","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"yoi220048r5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: opioid use disorder and COVID-19.","volume":"173","author":"Alexander","year":"2020","journal-title":"Ann Intern Med"},{"key":"yoi220048r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102905","article-title":"Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19.","volume":"93","author":"Davis","year":"2021","journal-title":"Int J Drug Policy"},{"key":"yoi220048r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102691","article-title":"Circumstances of overdose among street-involved, opioid-injecting women: drug, set, and setting.","volume":"78","author":"Ataiants","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"32","key":"yoi220048r8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic\u2014United States, June 24-30, 2020.","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"S1","key":"yoi220048r10","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1037\/tra0000660","article-title":"COVID-19, mental health, and opioid use disorder: old and new public health crises intertwine.","volume":"12","author":"Henry","year":"2020","journal-title":"Psychol Trauma"},{"issue":"5","key":"yoi220048r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0393","article-title":"Trends in filled naloxone prescriptions before and during the COVID-19 pandemic in the United States.","volume":"2","author":"O\u2019Donoghue","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"5","key":"yoi220048r19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/ADM.0000000000000779","article-title":"The impact of COVID-19 on service provision for emergency department patients post-opioid overdose: a field report.","volume":"15","author":"Collins","year":"2021","journal-title":"J Addict Med"},{"key":"yoi220048r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108283","article-title":"Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island.","volume":"124","author":"Clark","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"yoi220048r21","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/ADM.0000000000000809","article-title":"A telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system\u2019s initiative to expand treatment access during the COVID-19 pandemic.","volume":"16","author":"Tofighi","year":"2022","journal-title":"J Addict Med"},{"key":"yoi220048r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108590","article-title":"Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year.","volume":"133","author":"Bart","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"yoi220048r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108552","article-title":"Changes in methadone take-home dosing before and after COVID-19.","volume":"133","author":"Amram","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"yoi220048r24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/ADM.0000000000000812","article-title":"Reduction in Oregon\u2019s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication.","volume":"15","author":"McIlveen","year":"2021","journal-title":"J Addict Med"},{"issue":"4","key":"yoi220048r25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s11606-020-06436-3","article-title":"COVID-19 adaptations in the care of patients with opioid use disorder: a survey of California primary care clinics.","volume":"36","author":"Caton","year":"2021","journal-title":"J Gen Intern Med"},{"key":"yoi220048r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108543","article-title":"The COVID-19 pandemic and opioid use disorder: expanding treatment with buprenorphine, and combining safety precautions with telehealth.","volume":"133","author":"Cales","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"yoi220048r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108783","article-title":"Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.","volume":"225","author":"Jones","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yoi220048r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of Care for responding to the opioid epidemic.","volume":"45","author":"Williams","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"yoi220048r32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.amepre.2021.01.010","article-title":"Trends in opioid use disorder among older adults: analyzing Medicare data, 2013-2018.","volume":"60","author":"Shoff","year":"2021","journal-title":"Am J Prev Med"},{"key":"yoi220048r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108282","article-title":"Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in Medicare beneficiaries.","volume":"124","author":"Kuo","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"yoi220048r34","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1176\/appi.ps.202100088","article-title":"Addiction treatment and telehealth: review of efficacy and provider insights during the COVID-19 pandemic.","volume":"73","author":"Mark","year":"2022","journal-title":"Psychiatr Serv"},{"issue":"1","key":"yoi220048r35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention strategies for medications for opioid use disorder in adults: a rapid evidence review.","volume":"15","author":"Chan","year":"2021","journal-title":"J Addict Med"},{"issue":"5","key":"yoi220048r36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jama.2018.21932","article-title":"App aids treatment retention for opioid use disorder.","volume":"321","author":"Voelker","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"yoi220048r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.5852","article-title":"Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients.","volume":"3","author":"Kilaru","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"yoi220048r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"7","key":"yoi220048r41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1176\/appi.ps.201700315","article-title":"Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015.","volume":"69","author":"Roberts","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"11","key":"yoi220048r42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017-2018.","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"yoi220048r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"yoi220048r2","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine Committee on Medication-Assisted Treatment for Opioid Use Disorder","year":"2019"},{"key":"yoi220048r1","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families. Accessed March 17, 2022. https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf"},{"key":"yoi220048r3","unstructured":"US Centers for Disease Control and Prevention. Provisional drug overdose death counts. Accessed April 4, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"yoi220048r9","unstructured":"US Centers for Medicare & Medicaid Services. COVID-19 experiences among the Medicare population: fall 2020. Accessed March 19, 2022. https:\/\/www.cms.gov\/files\/document\/medicare-current-beneficiary-survey-covid-19-data-snapshot-infographic-fall-2020.pdf"},{"key":"yoi220048r12","unstructured":"US Department of Health and Human Services. Determination that a public health emergency exists. Accessed March 19, 2022. https:\/\/www.phe.gov\/emergency\/news\/healthactions\/phe\/Pages\/2019-nCoV.aspx"},{"key":"yoi220048r13","unstructured":"Federal Emergency Management Agency. COVID-19 disaster declarations. Accessed March 19, 2022. https:\/\/www.fema.gov\/disaster\/coronavirus\/disaster-declarations"},{"key":"yoi220048r14","unstructured":"US Centers for Medicare & Medicaid Services. Medicare payment policies during COVID-19. Accessed April 4, 2022. https:\/\/telehealth.hhs.gov\/providers\/billing-and-reimbursement\/medicare-payment-policies-during-covid-19\/"},{"key":"yoi220048r15","unstructured":"Chu? RC, Peters? C, De Lew? N, Sommers? BD. State Medicaid telehealth policies before and during the COVID-19 public health emergency. Accessed April 4, 2022. https:\/\/aspe.hhs.gov\/sites\/default\/files\/2021-07\/medicaid-telehealth-brief.pdf"},{"key":"yoi220048r16","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid treatment program (OTP) guidance. Accessed March 17, 2022. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf"},{"key":"yoi220048r17","unstructured":"Drug Enforcement Administration. Use of telephone evaluations to initiate buprenorphine prescribing. Accessed March 17, 2022. https:\/\/www.deadiversion.usdoj.gov\/GDP\/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf"},{"key":"yoi220048r18","unstructured":"US Center for Medicare and Medicaid Services. Opioid treatment programs (OTP). Accessed April 4, 2022. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/Opioid-Treatment-Program"},{"key":"yoi220048r28","unstructured":"US Centers for Medicare & Medicaid Services. Master Beneficiary Summary File (MBSF) Base. Accessed April 5, 2022. https:\/\/resdac.org\/cms-data\/files\/mbsf-base"},{"key":"yoi220048r29","unstructured":"US Centers for Medicare & Medicaid Services. Master Beneficiary Summary File (MBSF): 27 CCW Chronic Conditions segment. Accessed April 5, 2022. https:\/\/resdac.org\/cms-data\/files\/mbsf\u2013cc"},{"key":"yoi220048r31","unstructured":"Pharmacy Quality Alliance. Adherence: PQA adherence measures. Accessed March 19, 2022. https:\/\/www.pqaalliance.org\/adherence-measures"},{"key":"yoi220048r37","unstructured":"US Centers for Medicare & Medicaid Services. CMS behavioral health strategy. Accessed April 30, 2022. https:\/\/www.cms.gov\/cms-behavioral-health-strategy"},{"key":"yoi220048r38","unstructured":"US Department of Health and Human Services. Overdose prevention strategy. Accessed April 4, 2022. https:\/\/www.hhs.gov\/overdose-prevention\/"},{"key":"yoi220048r44","unstructured":"Office of Inspector General. Use of Medicare telehealth services during the COVID-19 pandemic. Accessed April 30, 2022. https:\/\/oig.hhs.gov\/reports-and-publications\/workplan\/summary\/wp-summary-0000491.asp"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2795953\/jamapsychiatry_jones_2022_oi_220048_1664208840.52473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:01:23Z","timestamp":1664967683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2795953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2284","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}